RNAi-based bio-switchable siRNA delivery composite material and preparation method and application thereof
By combining siRNA with nucleic acid cores, BiRDS structure is formed, and the stability and cell penetration of siRNA in bone defect repair is solved, efficient bone defect repair and cell osteogenesis and differentiation are achieved, providing new clinical treatment opportunities .
Patent Information
- Application Number
- CN202411109084.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-13
- Publication Date
- 2024-11-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing siRNA has limited half-life in the blood, is difficult to pass through the cell membrane, and has poor stability, resulting in limited application of its bone defect repair.
Design a biologically switchable siRNA delivery system based on RNAi. By combining siRNA with nucleic acid core, a new tetrahedral nucleic acid framework structure is formed, called BiRDS, using the concept of "Sun and Fairy Bird" to integrate miRNA inhibitors. In the tetrahedral scaffold, the stability and loading capacity of siRNA are improved and the configuration is changed in the cell is released by the RNase H reaction sequence.
Improve the stability of siRNA and cell uptake efficiency, extend the efficacy and safety of maxillofacial bone defects, significantly promote cell proliferation, migration and osteogenic differentiation, and provide a new treatment for critical maxillofacial bone defects. method.
Smart Images

Figure CN118995705A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to an RNAi-based bio-switchable siRNA delivery composite material, and a preparation method and use thereof. Background Art
[0002] Critical size defect (CSD) in the maxillofacial region caused by trauma, infection or tumor resection can have a series of effects on the patient's function and appearance. CSD cannot be completely healed by the body's own repair ability, so promoting defect repair through external intervention is currently one of the research hotspots in the field of bone regeneration.
[0003] CKIP-1, also known as Plekho1, is a regulatory protein. In recent years, it has been found that it exhibits multiple biological functions in cell morphology, cell proliferation and apoptosis, and plays different regulatory roles in different physiological processes (such as tumor formation, bone formation and immune regulation). It can interact with various proteins and signaling pathways through different domains, including PAK1, Arp2 / 3, c-Jun, ATM, Smurf1, Akt, etc. At present, it has only been confirmed that reducing CKIP-1 can improve primary or secondary osteoporosis and distraction osteogenesis, but it has not been applied to critical bone defects such as jaw defects so far, and the subsequent regulatory mechanism of CKIP-1 is still unclear.
[0004] Among the many regulatory technologies used to promote bone defect repair, RNA interference (RNAi) is a natural cellular process that regulates gene expression through a highly precise and sequence-targeted gene silencing mechanism, and can theoretically be used to target any pathogenic gene. RNAi is targeted and highly efficient. siRNA can effectively silence specific genes and accurately inhibit the expression of target genes with high specificity without affecting other genes. It can also rapidly degrade the mRNA of target genes, resulting in significant therapeutic effects. Therefore, for genes that have a negative regulatory effect on bone formation, RNAi therapy may be a very promising research direction for clinical application to treat diseases related to bone defects.
[0005] However, it is well known that siRNAs have a limited half-life in the blood, as they are rapidly degraded and cleared, which has hampered the widespread application of siRNA-based therapies. In addition, if a high dose of siRNA is required to achieve a good therapeutic effect of stimulating bone formation, there is a risk of adverse effects on non-bone tissues, which poses a major challenge to this field.
[0006] Tetrahedral nucleic acid frameworks (tFNAs) are composed of four independent DNA chains with specific base sequences. They self-assemble through the annealing process based on Watson-Crick base pairing to form a DNA nanostructure with a tetrahedral spatial shape, which has good stability and cell uptake ability. At the same time, tFNA itself also has good ability to promote cell proliferation, anti-inflammatory and antioxidant. The traditional first-generation tetrahedron carries RNA by pairing with the sticky end of RNA at the top through a pre-designed sticky end sequence. However, RNA bound to the outside of the tFNA structure still faces challenges during drug delivery. For example, the binding of the sticky end will expand the smaller nanostructure of the tetrahedron itself, affecting the optimal efficiency and stability of tFNA delivery to cells. In order to further improve the above problems, the research group designed the third-generation tetrahedron, a new type of biologically switchable miR inhibitor delivery system (BiRDS). This structure is inspired by the ancient Chinese mythology "The Sun and the Fairy Bird". It consists of three miR inhibitors (three fairy birds) and a nucleic acid core (the central sun). The miR inhibitors are fused inside the tetrahedral framework, which greatly improves its stability and RNA loading capacity, and does not expand the size of the tetrahedral framework structure, retaining the good tissue permeability and cell uptake brought by its extremely small size. After entering the cell, it can immediately change its configuration through the RNase H reaction sequence on the "bird" tail, releasing the carried RNA to play a role, which greatly improves the protection of the delivery system for RNA, which is extremely important for the recovery of bone defects.
[0007] In summary, although RNAi therapy can target and silence target genes, it has limitations such as difficulty in siRNA to cross the cell membrane, poor stability, and short half-life. Therefore, it is urgent to develop a siRNA delivery system with low toxicity, high stability, and efficient cell uptake to improve the efficacy and safety of critical size bone defect repair. Summary of the invention
[0008] In view of the problems of the prior art, the present invention provides an RNAi-based bio-switchable siRNA delivery composite material and a preparation method and use thereof.
[0009] A bio-switchable siRNA delivery system based on RNAi, characterized in that the system is composed of siRNA and a nucleic acid core, and the sense chain of the siRNA is a nucleotide sequence shown in SEQ ID NO.4 with two deoxynucleotides at the 3' end.
[0010] Preferably, it is composed of 3 siRNAs and 1 nucleic acid core;
[0011] Preferably, the nucleic acid core is composed of three DNA single strands, and the nucleotide sequences thereof are shown as SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3, respectively.
[0012] The present invention also provides a method for preparing the above-mentioned RNAi-based bio-switchable siRNA delivery system, comprising the following steps: mixing three DNA single strands with the siRNA, and incubating to obtain the system.
[0013] Preferably, the molar ratio of the three DNA single strands is 1:1:1, and the molar ratio of any one DNA single strand to the siRNA is 1:3.
[0014] The present invention also provides the use of the novel bio-switchable siRNA delivery system based on RNAi in treating critical-size bone defects in the maxillofacial region.
[0015] Preferably, the drug is used to promote BMSCs cell proliferation and / or migration;
[0016] Preferably, the drug is used to promote bone formation and / or repair;
[0017] Preferably, the drug promotes the expression of osteogenesis-related proteins.
[0018] The present invention also provides a drug for treating maxillofacial bone defects, characterized in that the drug is prepared by using an RNAi-based bio-switchable siRNA delivery system as an active ingredient and adding pharmaceutically acceptable excipients.
[0019] In the present invention, the biological switchable siRNA system (BiRDS) refers to: In order to improve the loading efficiency of tFNA, the inventor team has previously designed a biological switch miR inhibitor delivery system (BiRDS). The concept of this system comes from the "Sun and God Bird Delivery System" in ancient Chinese legends. It consists of three miRNA inhibitors and a nucleic acid core, the former metaphorically "BiRDS God Bird" and the latter symbolizing the "central sun". Unlike traditional tFNA, BiRDS cleverly integrates miRNA inhibitors into tetrahedral scaffolds, greatly improving its structural stability and RNA loading capacity. However, BiRDS has not been loaded with siRNAs for disease treatment, and its ability to load siRNAs and its subsequent effects in osteogenic biology need further exploration. (Reference: S.Li,Y.Liu,T.Zhang,S.Lin,S.Shi,J.He,Y.Xie,X.Cai,T.Tian,Y.Lin,ATetrahedral Framework DNA-Based Bioswitchable miRNA Inhibitor DeliverySystem:Application to Skin Anti-Aging,Adv Mater,(2022),34,e2204287DOI:10.1002 / adma.202204287.)
[0020] In order to improve the treatment strategy for critical-size bone defects in the maxillofacial region, the present invention designs a novel bio-switchable siRNA system carrying siCkip-1, which specifically targets the bone surface, efficiently silences the ckip gene, maximizes the loading capacity, promotes cell proliferation and migration, and has a good osteogenesis induction effect, providing new opportunities and methods for the treatment of clinical mandibular defects and critical bone defects in other parts of the body.
[0021] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.
[0022] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1The synthesis, verification, characterization and stability of BiRDS. (A) Schematic diagram of BiRDS structure. (B) Agarose gel electrophoresis experiment proves the successful synthesis of BiRDS. (C,D) Transmission electron microscopy and atomic force microscopy detect the distribution and morphological structure of tFNA and BiRDS. (E,I) Nanodistribution and Zeta potential of tFNA and BiRDS. (F) Detection of the stability of BiRDS. (G,H) Confocal microscopy and flow cytometry detect the intracellular efficiency of siRNA, tFNA and BiRDS (red: Cy5; blue: cell nucleus; green: cytoskeleton. Scale bar: 20μm.).
[0024] Figure 2 The scratch experiment was used to detect the effects of single chain, tFNA and BiRDS on BMSCs proliferation.
[0025] Figure 3 Transwell assay was used to detect the effects of single chain, tFNA and BiRDS on BMSCs cell migration.
[0026] Figure 4 The formation of calcium nodules was monitored by Alizarin Red S staining on day 21.
[0027] Figure 5 The osteogenic differentiation of BMSCs was observed by ALP staining on day 14.
[0028] Figure 6 This is the working principle of BiRDS. RNase H can recognize the DNA / RNA hybrid region of BiRDS, hydrolyze hydrogen bonds, and change the configuration of BiRDS from a three-dimensional tetrahedral configuration to a two-dimensional dart configuration, thereby separating the core framework structure and the external "Immortal Bird" structure, and releasing the "Immortal Bird" to the targeted site.
[0029] Figure 7 is the protein expression level of Ckip-1 and AKT.
[0030] Figure 8 Schematic diagram of the BIRDS structure.
[0031] Fig. 9 Cell immunofluorescence images of Ckip-1 and AKT.
[0032] Fig.10 RT-qPCR quantitative analysis results of Ckip-1 and AKT.
[0033] Fig.11 For protein expression level and quantitative analysis of Smad1 / 5, BMP2, β-catenin, and Wnt3a.
[0034] Fig.12These are the cell immunofluorescence images and quantitative analysis results of Smad1 / 5, BMP2, β-catenin, RUNX2, COL-1, and OSX.
[0035] Fig.13 Schematic diagram of the effect of BiRDS entering cells on the silencing of Ckip-1 and the Smad-BMP, Wnt3 a / β-catenin, and AKT signaling pathways.
[0036] Fig.14 The protein expression levels and semi-quantitative analysis results of ALP, RUNX2, OPN, COL-1, and OSX.
[0037] Fig.15 The results of RT-qPCR quantitative analysis of Smad1 / 5 and β-catenin.
[0038] Fig.16 3D reconstructions of the jaw defect area in rats after different treatments at 4 and 8 weeks.
[0039] Fig.17 Quantitative analysis of trabecular bone parameters (relative bone volume (BV / TV), trabecular thickness (Tb.Th), trabecular number (Tb.N) and trabecular space (Tb.Sp)) in the jaw defect area of rats after different treatments at 4 and 8 weeks.
[0040] Fig.18 Schematic diagram of in vivo drug loading methods and time nodes.
[0041] Fig.19 The distribution and metabolism of Cy5-labeled siRNA and BiRDS materials in rat mandible at 0, 12, 24, 48, 72, 96, and 120 hours using GELMA hydrogel in situ.
[0042] Fig. 20 HE and Masson staining images of the mandibular bones of rats at 4 and 8 weeks after treatment in different groups (scale bars: 200 μm and 100 μm).
[0043] Fig.21 Quantitative statistical diagram of new bone and mature bone in the mandible of rats at 4 and 8 weeks after different treatments.
[0044] Fig. 22 Immunohistochemical staining and quantitative analysis of Ckip protein in the mandibular bones of rats at 4 and 8 weeks after treatment with different groups.
[0045] Fig.23Immunofluorescence staining images of β-catenin, AKT, and Smad in mandibular bones and quantitative analysis of fluorescence intensity (β-catenin, AKT, Smad: red; cell nucleus: blue; Merge image) (Scale bar: 50 μm)
[0046] Fig.24 Immunofluorescence staining images of ALP, OPN, OSX, and BMP2 in the mandibular bones of rats at 4 and 8 weeks after treatment with different groups (osteoblasts: red; cell nuclei: blue; Merge images) (Scale bar: 50 μm)
[0047] Fig.25 Quantitative analysis of OSX, ALP, OPN, OSX, and BMP2 positive cell rates based on immunofluorescence images.
[0048] Data are expressed as mean ± standard deviation (SD) (n = 3). Statistical analysis: one-tailed < 0.05, two-tailed < 0.01, three-tailed < 0.001. * indicates "compared with the target of the control group", # indicates "compared with the target of the BiRDS group". DETAILED DESCRIPTION
[0049] In the following examples and experimental examples, reagents and raw materials not specifically described are all commercially available products.
[0050] Example 1 BiRDS and its preparation method
[0051] This embodiment provides a siCkip-1-based bio-switchable siRNA delivery composite (BiRDS), which is composed of three siRNAs and a nucleic acid core.
[0052] The nucleic acid core is composed of three nucleic acid chains (S1–3-BiRDS), and the nucleotide sequence S1 is shown in SEQ ID NO. 1: ggacuuggAGGATGGGCATGCTCTTCCCGACGGT ATTGGACCCTCGCATGAgcaaggaaAATG;
[0053] The nucleotide sequence S2 is shown in SEQ ID NO. 2: ggacuuggACATGCGAGGGTCC AATACCGACGATTACAGCTTGCTACACGAgcaaggaaAATG;
[0054] The nucleotide sequence S3 is shown in SEQ ID NO. 3: ggacuuggACGTGTAGCAAGCT GTAATCGACGGGAAGAGCATGCCCATCCAgcaaggaaAATG;
[0055] The siRNA nucleotide sequence is as follows:
[0056] sense(5'-3')GCGACAAGGUGCAGAAAGA(SEQ ID NO.4)dTdT; antisense(5'-3')UCUUUCUGCACCUUGUCGC(SEQ ID NO.5)dTdT.
[0057] The preparation method is as follows: add TM buffer (10 mm Tris-HCl and 50 mm MgCl2 dissolved in water, pH adjusted to 8.0 with hydrochloric acid) with an equimolar concentration of S1–3-BiRDS, and then add three times the concentration of siRNA. The complete oligonucleotide chain is incubated at 95°C for 10 minutes and 4°C for 20 minutes to synthesize BiRDS.
[0058] Comparative Example 1
[0059] This comparative example provides the control samples used in the experiment:
[0060] 1. tFNA
[0061] The sample is assembled from four ssDNAs (S1-4-T) based on base complementarity. The preparation method is the same as that in Example 1.
[0062] Wherein, the nucleotide sequence of single-stranded DNA S1 is shown in SEQ ID NO.6:
[0063] ATTTATCACCGCCATAGTAGACGTATCACCAGGCAGTTGAGACGAACATTCCTAAGTCTGAA;
[0064] The nucleotide sequence of single-stranded DNA S2 is shown in SEQ ID NO.7:
[0065] ACATGCGAGGGTCCAATACCGACGATTACAGCTTGCTACACGA
[0066] TTCAGACTTAGGAATGTTCG;
[0067] The nucleotide sequence of single-stranded DNA S3 is shown in SEQ ID NO.8:
[0068] ACTACTATGGCGGGTGATAAAACGTGTAGCAAGCTGTAATCGA
[0069] CGGGAAGAGCATGCCCATCC;
[0070] The nucleotide sequence of single-stranded DNA S4 is shown in SEQ ID NO.9:
[0071] ACGGTATTGGACCCTCGCATGACTCAACTGCCTGGTGATACGA
[0072] GGATGGGCATGCTCTTCCCG.
[0073] 2. SiRNA
[0074] This sample is siRNA that silences the Ckip-1 gene.
[0075] The siCkip-1 nucleotide sequence is as follows:
[0076] sense(5'-3')GCGACAAGGUGCAGAAAGA(SEQ ID NO.4)dTdT; antisense(5'-3')UCUUUCUGCACCUUGUCGC(SEQ ID NO.5)dTdT.
[0077] The technical solution of the present invention is further illustrated by experiments below.
[0078] Experimental Example 1 Design and Characterization of BiRDS
[0079] This experimental example characterizes the BiRDS system prepared in Example 1.
[0080] 1. Experimental Methods
[0081] The assembled tFNA and BiRDS were analyzed by GelRed-stained agarose gel (2%) electrophoresis (AGE) (120 V, 30 min) to verify the tetrahedral nanostructure of the materials, and the morphology of tFNA and BiRDS was observed using TEM and AFM. The particle size distribution and zeta potential of the two nanoparticles were measured using a Zetasizer Nano ZS90 system (Malvern, UK).
[0082] The stability of BiRDS and tFNA under serum conditions was evaluated by mixing the nanomaterials with 1-10% fetal bovine serum and incubating for 1 hour at 37°C. The nanomaterials were stored at room temperature (22°C) and 4°C for 1-7 days to evaluate the changes in storage stability of BiRDS and tFNA.
[0083] Cellular uptake: After BMSCs cells were seeded into confocal plates for adhesion, they were exposed to appropriate treatment conditions for 12 hours. Subsequently, the cells were labeled with DAPI (4,6-diamino-2-phenylindole) and FITC and then fixed in 4% paraformaldehyde for 30 minutes. For qualitative observation, fluorescent staining combined with laser confocal microscopy (FV3000, Olympus) was used; for quantitative detection of fluorescence intensity, flow cytometry (FC500, BECKMAN) was used. All data were analyzed using FLOW JO X software.
[0084] 2. Experimental Results
[0085] To demonstrate the effective synthesis of BiRDS, the 5' end of the siRNA was modified with a sulfocyanine 5 (Cy5) residue to show fluorescence. Agarose gel electrophoresis showed that the band size gradually increased with the gradual assembly and synthesis of the material. Finally, Cy5 fluorescence was observed in lane 8, confirming that the siRNA was successfully loaded into the BIRDS structure ( Figure 1 B).
[0086] Dynamic light scattering (DLS) showed that the diameters of tFNA and BiRDS were 7.31±0.72nm and 13.43±0.72nm, respectively, and the potentials were -6.91±2.97Mv and -11.84±0.51Mv, respectively. Figure 1 E, I). The size of BiRDS only slightly increased compared to tFNA, and still maintained a small nanostructure. Transmission electron microscopy (TEM) and atomic force microscopy (AFM) showed that BiRDS was evenly distributed in the solution and had a triangular stable structure. ( Figure 1 C, D).
[0087] First, a drug-serum stability experiment was conducted. 2% fetal bovine serum (FBS) was added to BiRDS to simulate the serum environment of BiRDS during subsequent use. The mixture was incubated at 37°C and verified using agarose gel electrophoresis (AGE). It was found that BiRDS maintained very good stability in a 2% fetal bovine serum environment, its structure was not destroyed, and the fluorescence intensity remained at 24 hours, which provided a solid foundation for the subsequent protection of siRNA to continue to function. In 10% serum, BiRDS could still detect weak fluorescence at 24 hours. Enzyme stability experiments showed that at 37°C, in lysis buffer, BiRDS could also preserve siRNA activity for at least 24 hours. At the same time, at 4°C, in TM buffer, BiRDS could be stored for at least 7 days, showing good storage stability.
[0088] To verify the cellular uptake of the prepared BiRDS, BMSCs were incubated with Cy5-labeled simple siRNA, Cy5-labeled tFNAs, or Cy5-labeled BiRDS for 12 and 24 h and analyzed by immunofluorescence and flow cytometry. Figure 1 H), 41.8% of tFNA and 40.7% of BiRDS particles penetrated the cell membrane after 12 hours, while only a small amount of pure siRNA was absorbed by BMSCs cells. After 24 hours, the absorption of pure siRNA was still low, while the efficiency of tFNA and BiRDS infiltrating cells was further greatly enhanced. Immunofluorescence results further confirmed the successful infiltration of BiRDS particles ( Figure 1 G).
[0089] The above experimental results indicate that siRNA was successfully loaded into the BiRDS structure and BiRDS exhibited good storage stability and ultrahigh cellular uptake efficiency, which would significantly enhance the osteogenic effect of siRNA.
[0090] Experimental Example 2: In vitro, investigating the therapeutic effect and regulatory mechanism of BiRDS system on maxillofacial bone defects
[0091] The SiRNA, tFNA and BiRDS samples used in this experimental example were prepared according to the method of Example 1 or Comparative Example 1.
[0092] 1. Experimental Methods
[0093] 1. Extraction, culture and treatment of primary rat BMSCs
[0094] Primary rat bone marrow-derived mesenchymal stem cells were isolated and cultured. Briefly, male Sprague Dawley rats were sacrificed and sterilized in 75% ethanol for 15 minutes. The femur was separated and the bone marrow-derived MSCs were collected by flushing with α-MEM using a syringe under sterile conditions. The aspirate was centrifuged at 800 rpm for 5 minutes, resuspended and maintained in α-MEM supplemented with 10% fetal bovine serum containing 100 U / mL penicillin and 100 μg / mL streptomycin. The culture medium was changed twice a week, and the 3rd-5th passages were used for further cell inoculation.
[0095] 2. Cell proliferation assay
[0096] BMSCs cells (5000 cells / well) were seeded into 96-well plates. After the cells were exposed to the necessary treatment conditions for 24 hours, CCK-8 (10 μL) was added and incubated at 37°C for 4 hours. After incubation, the absorbance at 450 nm of each cell was obtained using a Tecan microplate reader.
[0097] 3. CCK8
[0098] CCK-8 assay was performed using CCK-8 kit according to the manufacturer’s instructions. Briefly, rBMSCs were cultured in 24-well plates at a density of 5 × 10 cells per well in different scaffolds. After 1, 3, and 5 days of culture, the culture medium was replaced with 10% CCK-8 solution and then incubated at 37 °C for another 30 min.
[0099] 4. Migration test
[0100] In order to evaluate the migration ability of BMSCs in various environments, a scratch test was performed. Each well of a 6-well plate was filled with 5×10 5 cells per plate. Using a sterile pipette tip, a cross-shaped scratch was made on the bottom of each plate. The cells were then treated in serum-free TM buffer, tFNA, or serum-free α medium for 12 hours. They were then rinsed with PBS. After 0, 4, and 8 hours, the extent of cell migration was measured using an Olympus microscope.
[0101] 5. ALP staining and ALP quantification
[0102] For ALP staining analysis, rBMSCs were incubated for 7 and 14 days and then fixed with 4% paraformaldehyde for 15 minutes and then gently washed. Next, ALP staining was performed using an NBT / BCIP staining kit according to the manufacturer's instructions. Photos were taken for further analysis. For quantitative ALP assay, rBMSCs were lysed using RIPA buffer after 7 and 14 days of incubation. Subsequently, ALP levels were determined using an ALP detection kit. Quantitative analysis was performed based on the generation of OD p-nitrophenol, which reflects the ALP content. To standardize the ALP activity level, protein levels were measured using a BCA detection kit.
[0103] 6. Alizarin red staining and semi-quantitative analysis
[0104] For Alizarin Red staining, rBMSCs were fixed with 4% paraformaldehyde for 15 min after an incubation period of 14 and 21 days, respectively. After gentle rinsing, the cells were stained with ARS solution. Images were subsequently taken for detailed analysis. For semi-quantitative evaluation, 10% hexadecylpyridinium chloride was added to the stained wells for 20 min, and then the OD readings of the supernatant were recorded at a wavelength of 562 nm.
[0105] 2. Experimental Results
[0106] 1. BiRDS promotes cell proliferation, migration and osteogenic differentiation through the AKT signaling pathway
[0107] The results of CCK-8 experiments showed that BiRDS and tFNA stimulated the growth of BMSCs cells, while siRNA only slightly promoted proliferation. The results of the wound closure test showed that the number of BMSCs cells closed in the BIRDS group was higher than that in the simple siRNA group within 6h, 12h, and 24h of the scratch, while there was no significant difference between the simple siRNA group and the control group ( Figure 2 The intensity of crystal violet in the Transell experiment further proved that BiRDS has an excellent effect on BMSCs migration compared with simple siRNA ( Figure 3 ).
[0108] RT-qPCR results showed that compared with the control group, BiRDS loaded with siRNA could silence the target gene (~60%) on the third day, which was about 2 times higher than the silencing of Ckip-1 in the single Ckip-1 siRNA group. One week later, the target gene had recovered to 90% in the treatment containing pure Ckip-1 siRNA. However, ckip-1 in the BiRDS transfection group remained at a low level, and this silencing effect still existed, which proved the sustained effect of the BiRDS system on carrying siRNA and the good target gene silencing effect ( Fig.10 ).
[0109] qPCR results showed that treatment of BMSCs with BiRDS could upregulate AKT. The expression level of AKT protein was also analyzed by WB ( Figure 7 ) and immunofluorescence staining ( Fig. 9 ) further confirmed that BiRDS significantly promoted the expression of AKT compared with the other groups, thereby promoting cell migration and proliferation.
[0110] ALP staining results showed that ( Figure 5 ), after 14 days of osteogenic induction, all groups showed purple staining, and the staining depth and density of the BiRDS group were significantly higher than those of the positive control group induced by simple osteogenic medium, with the strongest osteogenic ability, while the osteogenic ability of simple siRNA was the weakest. After 21 days of incubation, the same trend was observed in the ARS staining results. The staining results showed that the staining depth and density of calcium nodules in the BiRDS group were higher than those in the positive control group ( Figure 4 ), quantitative analysis of ALP and ARS contents ( Figure 4 ,5) further confirmed these conclusions.
[0111] The above experimental results show that the BiRDS system has a good target gene silencing effect, and promotes cell proliferation, migration and osteogenic differentiation through the AKT signaling pathway, thereby playing a role in treating maxillofacial bone defects.
[0112] 2. BiRDS promotes osteogenesis by activating the BMP-Smad signaling pathway
[0113] The results of confocal microscopy and WB showed that the BiRDS group showed a significant therapeutic effect on the increase of Smad protein expression. The content was increased to more than 2 times that of the control group ( Fig.11 , 12). The gene expression level was more prominent than the immunofluorescence and WB results. Fig.12 It was found that the siRNA group increased the Smad1 / 5 gene level by nearly 4 times, while the BiRDS group increased it by nearly 10 times. The promoting effect of Smad is more obvious at the gene level than at the protein level.
[0114] The above experimental results confirm that CKIP protein may interact with Smad protein in the BMP (Bone Morphogenetic Protein) signaling pathway to affect the proliferation and differentiation of jaw cells. BiRDS can carry siRNA to efficiently activate the BMP-Smad signaling pathway, which plays a key role in bone formation and repair.
[0115] 3. BiRDS promotes osteogenesis by regulating the Wnt3 a / β-catenin pathway
[0116] WB results showed that Wnt3a in the BiRDS group was significantly upregulated compared with the other two groups. However, the expression levels in the siRNA group and the control group were not high, and there was no statistical difference between the two. ( Fig.11 ). For β-catenin, the expression level in the BiRDS group was more than twice that of the control group. The results of cell immunofluorescence showed that the protein expression intensity of β-catenin increased by up to 10 times in the BIRDS group compared with the control group, while it only increased by 2 times in the simple siRNA group ( Fig.12 ). BIRDS has a good effect on promoting the Wnt3a / β-catenin pathway.
[0117] The WB results showed that ( Fig.14 ), the expression of ALP, RUNX2, OPN, COL-1, and OSX proteins in the BiRDS group were upregulated compared with the control group and TFNA group, with significant statistical differences. The results of immunofluorescence were consistent with those of western blotting experiments, especially COL-1 and RUNX2, which showed great improvement advantages in the cell immunofluorescence experiment.
[0118] The above experimental results show that BiRDS, as an excellent siR delivery system, can treat bone defects by promoting the Wnt3a / β-catenin pathway.
[0119] Experimental Example 3: In vivo study of the repair effect and regulatory mechanism of the BiRDS system on mandibular defects in rats
[0120] The SiRNA, tFNA and BiRDS samples used in this experimental example were prepared according to the method of Example 1 or Comparative Example 1.
[0121] 1. Experimental Methods
[0122] 1. Experimental Animals
[0123] Thirty-two 6-week-old SPF male SD rats (Chengdu Dashuo Experimental Animal Co., Ltd., China) were selected. The mice were randomly divided into GelMA group, siRNA / GelMA group, tFNA / GelMA group, and BIRDS / GelMA group, with 5 rats in each group. SPF rats were fed with maintenance feed, and sterile drinking water and bedding were changed 2-3 times a week.
[0124] 2. Establishment of mandibular defect model
[0125] First, mice were anesthetized by inhalation of isoflurane, and the skin of the left mandibular surgical area of rats was prepared and disinfected. A 6mm incision was made at the projection of the mandibular ramus, and the mandible was exposed after blunt separation of soft tissue. A 3mm full-thickness bone defect was made in the mandibular body using a trephine drill as a critical bone defect model, and the bone chips were fully rinsed with saline. The GelMA group, siRNA / GelMA group, tFNA / GelMA group, and BIRDS / GelMA group were pre-cured for 10 seconds and injected into the bone defect, and then light-cured for 6 seconds. Finally, the incision was sutured with 5-0 sutures and disinfected again. At 4 and 8 weeks after surgery, the mice were killed by cervical dislocation, and the mandible was removed after stripping the soft tissue. After washing with 1×PBS, the samples were fixed in 4% paraformaldehyde solution for 48 hours for subsequent histological experiments.
[0126] 3. Micro-CT Scanning
[0127] The samples were scanned using micro-CT (Scanco, Switzerland). The scanning parameters were: accuracy 10μm, voltage 70kVp, current 200μA. Three-dimensional reconstruction and bone parameter analysis were performed using Scanco's supporting analysis software. The region of interest (ROI) was defined as a full-thickness circular bone defect area of the mandible with a diameter of 2.3mm. Bone parameter analysis included bone volume over total volume (BV / TV) and mean density of bone volume.
[0128] 4. Histological staining
[0129] 10% EDTA (pH 7.2-7.5) was used for decalcification. The decalcification solution was changed every 2 days. The decalcification was completed in about 4 weeks. The residual decalcification solution was rinsed under running water overnight. After paraffin embedding, the sections were dewaxed and rehydrated, and Masson staining was performed according to the instructions of the Masson staining kit (Sevier Bio, China). Paraffin sections were dewaxed and rehydrated, and antigen retrieval was performed using 1× sodium citrate antigen retrieval solution (Biyuntian, China). Washed twice with 1× PBS, 5 minutes each time. Blocked with normal goat serum (Zhongshan Jinqiao, China) at room temperature for 30 minutes. After draining, the primary antibody diluted with antibody diluent (COL1A1: 1:200, ALP: 1:200) was added and incubated at 4°C overnight. After washing with PBST, iFluor 488-labeled goat anti-rabbit secondary antibody (1:1000) diluted with antibody diluent was added, and incubated in a shaker at room temperature for 1 hour in the dark, and washed 3 times with PBST, 5 minutes each time. After staining with DAPI for 10 minutes, the slides were washed once with PBST, autofluorescence quenching kit (VectorLabs, USA) was used to reduce autofluorescence, and the slides were sealed and scanned using a full slide scanning system (Olympus, Japan).
[0130] 5. Statistical analysis
[0131] All biological tests were performed at least three times, and the results were reported as mean ± standard deviation. Data analysis was performed using GraphPad Prism9.0 software (GraphPad Software, CA, USA). When comparing two groups of data, a one-tailed t-test was used to determine statistical significance, while a one-way analysis of variance (ANOVA) with Bonferroni post hoc correction was applied to compare the mean values of more than two groups. P < 0.05 was considered significant, and P < 0.01 or < 0.001 was considered to indicate very high statistical significance.
[0132] 2. Experimental Results
[0133] 1. Pharmacokinetics of BiRDS and its repair effect on mandibular defects in rats
[0134] In vivo fluorescence imaging system (IVIS) was used to verify the biodistribution and retention time of the drug. Fig.19As shown in the figure, the fluorescence intensity of Cy5-labeled siRNA in the jawbone slowly decreased in the first 24 hours, then rapidly decreased after 24-48 hours, and basically disappeared completely in the jawbone after only 120 hours. The fluorescence intensity of Cy5-labeled BIRDS in the jawbone remained basically unchanged in the first 24 hours, and then decreased significantly after 24-72 hours, but was higher than that of the simple siRNA group at each time point, and slowly decreased after 72 hours, and the fluorescence intensity remained high after 120 hours. The results show that BIRDS stays in the jaw defect for a longer time, which is related to the good tissue retention and permeability of BIRDS.
[0135] The three-dimensional reconstruction images of micro-CT scanning showed that at 4 weeks, the control group and siRNA group had poor repair effects on the mandibular defect, and the new bone formation area only covered about 10% of the bone defect. BiRDS had a good repair effect on the mandibular defect, and the new bone coverage had reached 40% of the entire defect, proving the good bone formation effect brought by the silencing effect of BIRDS on ckip in the early stage. At 8 weeks, I can observe that the healing of the BIRDS group is more obvious, reaching 70%, while the simple siRNA group and the blank group still have large defects and show no signs of repair ( Fig.16 ).
[0136] Bone parameter analysis of the defect area showed that ( Fig.17 ), at the 4th and 8th week, the bone volume fraction (BV / TV) of the BiRDS group and the TFNA group was higher than that of the siRNA group and the control group, among which the value of the BiRDS group was the highest, and there was no significant difference in the mean density of bone voxel (BV) in the defect area of the four groups. The BV / TV and Tb.Th (10.01% and 10.56%, respectively) of the Ckip siRNA group alone at the 4th week after treatment increased compared with the control group (P<0.05), but at the 8th week, the increase in the above bone volume parameters was not obvious enough, while the BIRDS group always had a stable and long-term osteogenic effect over time, whether it was the 4th week or the 8th week.
[0137] H&E ( Fig. 20 ), the yellow dotted line represents the boundary between old bone and new bone. We can see that at 4 weeks, the bone defect area in the blank group and the simple siRNA group was not healed much. In the BiRDS group, new bone formation appeared in about 1 / 2 of the defect area, gradually expanding from the periphery of the defect to the center. , Masson staining results showed ( Fig. 20), at 4 weeks, the blue area in the BIRDS group was obvious, with many new trabeculae, and in the enlarged image, it can be seen that there are more and larger osteocytes in the new bone, and the activity is vigorous. At week 8, the new trabeculae in the BIRDS group transitioned from blue to red (mature bone), and bone repair was active, gradually transitioning from trabeculae to lamellar bone. At different time stages of bone regeneration, the new bone and mature bone area in the defect area of the BiRDS group were larger than those of the other groups, and BIRDS showed superior therapeutic effects at different times.
[0138] The above experimental results show that BIRDS has a good effect on repairing mandibular defects and can promote new bone formation.
[0139] 2. The knockdown efficiency of Ckip and the promotion of osteogenesis-related pathways by BiRDS in the repair of mandibular defects in rats
[0140] Immunohistochemical staining directly analyzed the expression of Ckip protein in mandibular tissue. After administration of siRNA delivered by BIRDS, basically no Ckip-positive cells were observed at 4 and 8 weeks. In the tFNA group, Ckip expression did not change at all. In the siRNA alone group, we found that knockdown of the Ckip gene in the treated bones also had a certain effect, but the efficiency was far less than that of the BIRDS group. In the late treatment period (8 weeks), the number of Ckip-positive cells in the siRNA alone group increased significantly compared with the 4th week (P>0.05) ( Fig. 22 ). This indicates that the duration of Ckip silencing cannot reach 8 weeks, and the therapeutic effect can only be limited in the short term.
[0141] To further verify the effective regulation of target genes by BiRDS, we detected the expression levels of positive regulatory signal proteins related to the osteogenic pathway or proteins related to cell proliferation. During the 4-week observation period, it was found that the expression of Smad and β-catnin proteins in the BiRDS group increased significantly; AKT phosphorylation was promoted, and cell proliferation activity was enhanced; these factors promoted the rapid healing of bone tissue in bone defects ( Fig.23 ). In contrast, the expression of these proteins in the siRNA group alone reached a low level. The tFNA group also promoted the expression of Smad, β-catnin, and AKT in jaw defects, indicating that tFNA, as a carrier itself, has high potential
[0142] The above experimental results show that the BiRDS system can silence the Ckip gene more efficiently, promote the expression level of osteogenic pathway-related proteins or cell proliferation-related proteins, thereby improving the therapeutic effect.
[0143] 3. The promoting effect of BiRDS on osteogenic related proteins in mandibular defect repair in rats
[0144] To further confirm the potential mechanism of BIRDS in promoting osteogenesis in the jaw of rats, immunofluorescence staining was used to evaluate the activity of osteogenic markers. The expression levels of OPN, Col-1, BMP2, and ALP in the jaw defect area were measured by calculating the relative fluorescence intensity. The quantitative analysis results of immunofluorescence sections showed that the expression of OPN and BMP2 in the BIRDS group was upregulated, and the overall fluorescence intensity of related proteins also increased. Similarly, the immunofluorescence results of ALP in each group showed that the expression level of ALP in the periosteum of the BiRDS group was higher, indicating that osteogenesis may be actively proceeding, while the ALP-positive areas in the other three groups were not as obvious as in the BIRDS group. The immunofluorescence results of COL1 showed that the content of type I collagen in the bone of the BiRDS group was higher, indicating that bone regeneration was more active than that of the blank group and the simple siRNA group, and its increase was nearly 2 times that of the simple siRNA group ( Fig.24 , 25).
[0145] The above experimental results show that BiRDS comprehensively improves the expression level of osteogenesis-related proteins in rat jaw defects and promotes osteogenesis in rat jaws.
[0146] The above experimental examples show that BiRDS exhibits good storage stability and ultra-high cell uptake efficiency, can effectively silence the Ckip gene, promote cell proliferation, migration and osteogenic differentiation, and has good osteogenesis induction and bone repair effects. Its regulatory mechanism is related to the AKT pathway, Wnt / β-catnin pathway, and Smad-BMP2 pathway. It is a targeted delivery system with broad prospects.
[0147] Therefore, constructing a delivery system of BiRDS carrying siRNA provides new opportunities and methods for the treatment of clinical jaw defects and critical bone defects in other parts of the body, and has great clinical potential.
Claims
1. A bio-switchable siRNA delivery system based on RNAi, characterized in that: The system is composed of siRNA and a nucleic acid core. The sense strand of the siRNA is a nucleotide sequence shown in SEQ ID NO. 4 with two deoxynucleotides at the 3' end.
2. The RNAi-based bio-switchable siRNA delivery system according to claim 1, characterized in that: It is composed of 3 siRNAs and 1 nucleic acid core.
3. The RNAi-based bio-switchable siRNA delivery system according to claim 2, characterized in that: The nucleic acid core is composed of three DNA single strands, and the nucleotide sequences of the DNA single strands are shown as SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3, respectively.
4. The method for preparing the RNAi-based bio-switchable siRNA delivery system according to any one of claims 1 to 3, characterized in that: The method comprises the following steps: mixing three kinds of DNA single strands with the siRNA, and incubating them to obtain the product.
5. The RNAi-based bio-switchable siRNA delivery system according to claim 4, characterized in that: The molar ratio of the three DNA single strands is 1:1:1, and the molar ratio of any one DNA single strand to the siRNA is 1:
3.
6. Use of the novel bio-switchable siRNA delivery system based on RNAi according to any one of claims 1 to 3 in the treatment of critical-size bone defects in the maxillofacial region.
7. The use according to claim 6, characterized in that: The medicine is used for promoting the proliferation and / or migration of BMSCs.
8. The use according to claim 6, characterized in that: The medicament is used to promote bone formation and / or repair.
9. The use according to claim 6, characterized in that: The drug promotes the expression of osteogenesis-related proteins.
10. A drug for treating maxillofacial bone defects, characterized in that: The invention is prepared by taking the RNAi-based bio-switchable siRNA delivery system as any one of claims 1 to 3 as an active ingredient and adding pharmaceutically acceptable excipients.
